Transmembrane protein 53 (TMEM53)

Transmembrane protein 53 (TMEM53) is a single-pass transmembrane protein encoded by the TMEM53 gene located on human chromosome 1[1][6]. The protein is predominantly localized to the nuclear envelope and is characterized by a highly conserved domain called DUF829, which comprises the majority of its sequence[1]. TMEM53 has a molecular weight of ~31.6 kDa and is predicted to contain alternating alpha helices and beta sheets in its secondary structure. TMEM53 is ubiquitously expressed at low levels across normal and cancerous tissues, with some tissue-specific variations in expression[1]. Functionally, TMEM53 acts as a negative regulator of bone morphogenetic protein (BMP) signaling by blocking the nuclear translocation of phosphorylated SMAD1/5/9 proteins in osteoblast lineage cells, thereby ensuring normal bone formation and negatively regulating ossification[2][6]. Mutations or deficiencies in TMEM53 have been linked to rare bone disorders such as craniotubular dysplasia Ikegawa type and craniodiaphyseal dysplasia[2][4]. The protein has no known human paralogs but has numerous eukaryotic orthologs, indicating evolutionary conservation[1]. Currently, there are no known drugs that directly target TMEM53, nor is it recognized as a common biomarker for patient selection or efficacy monitoring. The protein is not considered a classical therapeutic target (e.g., receptor, enzyme) but is implicated in rare bone diseases due to its regulatory effect on BMP signaling. Safety concerns and detailed therapeutic challenges for TMEM53 targeting have not been described in the available literature[2][6][4].

Other names

TMEM53NET4FLJ22353CTDInuclear envelope transmembrane protein 4novel DUF829 domain-containing proteinRP4-678E16.2